DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Monopril (Fosinopril Sodium) - Published Studies


Monopril Related Published Studies

Well-designed clinical trials related to Monopril (Fosinopril)

Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). [2011.06]

Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. [2010.06]

Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. [2008.01]

Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. [2006.10]

Racial differences are seen in blood pressure response to fosinopril in hypertensive children. [2006.08]

Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. [2006.07]

The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency. [2006.05]

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). [2006.03]

[Head-to-head comparison of clinical, biochemical and functional effects of fosinopril and enalapril in patients with systolic heart failure] [2006.01]

Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension. [2005.03]

Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. [2005.03]

Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. [2004.12]

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. [2004.11.02]

Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? [2004.09]

Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. [2004.07]

A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis. [2003.01]

Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. [2002.12]

[Comparison of the antihypertensive activity of fosinopril and irbesartan] [2002.11]

FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics. [2002.10]

The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. [2002.10]

Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild to moderate essential hypertension. [2002.05]

Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. [2002.01.29]

A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. [2001.10]

Comparison of the first dose response of fosinopril and captopril in congestive heart failure: a randomized, double-blind, placebo controlled study. [2001.03]

Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). [2000.09.15]

Effects of fosinopril or sustained-release verapamil on blood pressure and serum catecholamine concentrations in elderly hypertensive men. [2000.01]

Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. [2000.01]

Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. [1999.09]

The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. [1999.07]

Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction. [1999.05]

Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure. [1999.03]

Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects. [1999.02]

Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. [1999.02]

Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET) [1998.11.12]

Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. [1998.10]

Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. [1998.08]

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. [1998.04]

Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS). [1997.10]

An effective approach for treating elderly patients with isolated systolic hypertension: results of an Italian multicenter study with fosinopril. [1997.10]

Well-designed clinical trials possibly related to Monopril (Fosinopril)

Pharmacotherapy review of chronic pediatric hypertension. [2011.10]

Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile. [2010.06]

Combination therapy with angiotensin-converting enzyme inhibitors and indapamide impairs glucose tolerance in Chinese hypertensive patients. [2010.04]

Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. [2010.03.25]

Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients. [2010.03]

ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. [2010.01]

Prostaglandin E1 for preventing the progression of diabetic kidney disease. [2010]

Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. [2010]

Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients. [2009.07]

Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. [2009.02]

Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. [2007.12]

[Observation on therapeutic effects of combined acupuncture and medicine therapy and simple medication on renal hypertension of chronic kidney disease] [2007.09]

[Multicentered, randomized, controlled clinical trial on patients with IgA nephropathy of Qi-yin deficiency syndrome type] [2007.02]

[Prospective, multi-centered, randomized and controlled trial on effect of shenle capsule in treating patients with IgA nephropathy of Fei-Pi qi-deficiency syndrome] [2006.12]

Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. [2006.11]

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. [2006.11]

Clinical study on effect of Garlicin in stabilizing the carotid artery atherosclerotic plaque in patients with primary hypertension and coronary artery disease. [2006.09]

Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. [2006.04]

Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. [2005.07]

Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk. [2005.03]

Framingham score and microalbuminuria: combined future targets for primary prevention? [2004.11]

Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. [2003.11]

Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. [2003.10]

Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. [2003.09]

Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. [2003.06]

Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. [2002.10]

Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men. [2002.09]

Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. [2001.01]

[The estimation of cardiovascular risk in hypertensive patients is not modified by management of the hypertension] [2000.08]

Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension. [2000.08]

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. [2000.07]

In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor. [2000.06]

Is the tissue affinity of ACE inhibitors of relevance for the remodeling of the left ventricular wall following myocardial infarction? Estimations with cine magnetic resonance imaging. [2000]

[Effect of ACE-inhibitors on left ventricular remodeling after acute anterior or posterior myocardial infarct. Cine- magnetic resonance tomography study] [2000]

Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. [1999.04]

The extent of regional wall motion abnormalities identifies patients at risk of extensive left ventricular remodeling: implications for the design of post myocardial infarction trials. [1999.01]

Prostacyclin: its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism. [1999]

Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men. [1999]

Calcium antagonists and the diabetic patient: a response to recent controversies. [1998.11.12]

Regression of left ventricular wall thickness during ACE-inhibitor treatment of essential hypertension is associated with an increase in insulin mediated skeletal muscle blood flow. [1998.05]

Influence of tissue affinity of angiotensin-converting enzyme inhibitors on left ventricular remodeling after myocardial infarction. [1998.04]

New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. [1998]

A prospective comparison of four study designs used in assessing safety and effectiveness of drug therapy in hypertension management. [1997.11]

Other research related to Monopril (Fosinopril)

Fosinopril-cyclodextrin inclusion complexes: phase solubility and physicochemical analysis. [2011.08]

Effects of fosinopril and losartan on renal Klotho expression and oxidative stress in spontaneously hypertensive rats. [2011.01]

Fosinopril and losartan regulate klotho gene and nicotinamide adenine dinucleotide phosphate oxidase expression in kidneys of spontaneously hypertensive rats. [2011]

Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats. [2010.10]

[Protective effect of fosinopril sodium pretreatment combined with ischemic postconditioning on rat heart underwent myocardial ischemia/reperfusion injury]. [2010.07]

Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. [2010]

[Plasma tissue factor and serum angiotensin II and the therapeutic effect of different dosages of fosinopril on chronic heart failure] [2009.05]

Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. [2008.12]

Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. [2008.07.15]

Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. [2007.12]

Other possibly related research studies

Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. [2008.06]

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. [2008.05.27]

Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. [2008.05.06]

Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats. [2008.02]

Comparison of persistence rates with angiotensin-converting enzyme inhibitors used in secondary and primary prevention of cardiovascular disease. [2007.09]

Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty. [2007.03]

Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. [2007.04]

Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. [2008.10]

Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension. [2008.09]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017